NERV (Minerva Neurosciences) Short Interest


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.32
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NERV vs YDES, CAMP, IKT: Short Interest Comparison

For the Biotechnology subindustry, Minerva Neurosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Short Interest falls into.


NERV
32GF Score
Minerva Neurosciences Inc NERV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.32
Price